Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Elvitegravir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 1/20 | 1.00 |
| ▸ | PLA2G4A | P47712 | 5/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 4/20 | 0.36 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CMA1 | P23946 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Elvitegravir SCHEMBL726251 | 1.00 | METTL3 (1.00) | METTL3PLA2G4AMAPTGAATP53 | |
| Elvitegravir SCHEMBL726252 | 1.00 | METTL3 (1.00) | METTL3PLA2G4AMAPTGAATP53 | |
| Elvitegravir SCHEMBL29623981 | 1.00 | METTL3 (1.00) | METTL3PLA2G4AMAPTGAATP53 | |
| Elvitegravir SCHEMBL1050769 | 0.99 | METTL3 (0.98) | METTL3PLA2G4AMAPTGAATP53 | |
| Elvitegravir SCHEMBL1050765 | 0.99 | METTL3 (0.98) | METTL3PLA2G4AMAPTGAATP53 | |
| Elvitegravir SCHEMBL2280863 | 0.94 | METTL3 (0.89) | METTL3PLA2G4AMAPTGAATP53 | |
| Elvitegravir SCHEMBL31577400 | 0.94 | METTL3 (0.88) | METTL3PLA2G4AMAPTGAATP53 | |
| SCHEMBL4366707 | 0.94 | METTL3 (0.88) | METTL3PLA2G4AMAPTGAATP53 | |
| SCHEMBL1104875 | 0.93 | METTL3 (0.88) | METTL3PLA2G4AMAPTGAAEGFR | |
| SCHEMBL19829420 | 0.93 | METTL3 (0.88) | METTL3PLA2G4AMAPTGAAEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3870174-B1 | ANTIVIRAL PRODRUGS AND NANOFORMULATIONS THEREOF | UNIV NEBRASKA (US) | 2023-11-01 | — | — | EP | disclosed |
| WO-2023183472-A1 | ANTIVIRAL PRODRUGS AND USE THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2023-09-28 | — | — | WO | disclosed |
| EP-4234561-A2 | ANTIVIRAL PRODRUGS AND NANOFORMULATIONS THEREOF | Board of Regents of the University of Nebraska (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-4234560-A2 | ANTIVIRAL PRODRUGS AND NANOFORMULATIONS THEREOF | Board of Regents of the University of Nebraska (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20220211716-A1 | ANTIVIRAL PRODRUGS AND NANOFORMULATIONS THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2022-07-07 | — | — | US | disclosed |
| US-11166957-B2 | Antiviral prodrugs and nanoformulations thereof | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2021-11-09 | — | — | US | disclosed |
| US-20210275535-A1 | ANTIVIRAL PRODRUGS AND NANOFORMULATIONS THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-09-09 | — | — | US | disclosed |
| WO-2020112931-A1 | ANTIVIRAL PRODRUGS AND NANOFORMULATIONS THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2020-06-04 | — | — | WO | disclosed |
| US-20190185433-A1 | STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND | JAPAN TOBACCO INC. (JP) | 2019-06-20 | — | — | US | disclosed |
| EP-2906540-B1 | AN IMPROVED PRODUCTION METHOD AND NEW INTERMEDIATES OF SYNTHESIS OF ELVITEGRAVIR | ZENTIVA KS (CZ) | 2018-07-04 | — | — | EP | disclosed |
| EP-2906529-B9 | A NEW PRODUCTION METHOD AND NEW INTERMEDIATES OF SYNTHESIS OF ELVITEGRAVIR | ZENTIVA KS (CZ) | 2017-03-15 | — | — | EP | disclosed |
| EP-2906529-B9 | A NEW PRODUCTION METHOD AND NEW INTERMEDIATES OF SYNTHESIS OF ELVITEGRAVIR | ZENTIVA KS (CZ) | 2017-03-15 | — | — | EP | disclosed |
| EP-2906529-B1 | A NEW PRODUCTION METHOD AND NEW INTERMEDIATES OF SYNTHESIS OF ELVITEGRAVIR | ZENTIVA KS (CZ) | 2016-11-23 | — | — | EP | disclosed |
| EP-2906529-A1 | A NEW PRODUCTION METHOD AND NEW INTERMEDIATES OF SYNTHESIS OF ELVITEGRAVIR | Zentiva K.S. (CZ) | 2015-08-19 | — | — | EP | disclosed |
| US-8981103-B2 | Stable crystal of 4-oxoquinoline compound | JAPAN TOBACCO INC. (JP) | 2015-03-17 | — | — | US | disclosed |
| US-8981103-B2 | Stable crystal of 4-oxoquinoline compound | JAPAN TOBACCO INC. (JP) | 2015-03-17 | — | — | US | disclosed |
| WO-2014056464-A1 | A NEW PRODUCTION METHOD AND NEW INTERMEDIATES OF SYNTHESIS OF ELVITEGRAVIR | ZENTIVA, K.S. (CZ) | 2014-04-17 | — | — | WO | disclosed |
| WO-2014056465-A1 | AN IMPROVED PRODUCTION METHOD AND NEW INTERMEDIATES OF SYNTHESIS OF ELVITEGRAVIR | ZENTIVA, K.S. (CZ) | 2014-04-17 | — | — | WO | disclosed |
| US-20100204271-A1 | STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND | JAPAN TOBACCO INC. | 2010-08-12 | — | — | US | disclosed |
| US-20100204271-A1 | STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND | JAPAN TOBACCO INC. | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210275535-A1 | ANTIVIRAL PRODRUGS AND NANOFORMULATIONS THEREOF | TYMP, PNP, SLC29A1 | METTL3 466/4885PLA2G4A 1301/4885MAPT 2826/4885 |
| US-20100204271-A1 | STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND | GRIN2D, KCNQ2, RCC1 | METTL3 200/4885PLA2G4A 4223/4885MAPT 589/4885 |
| US-20190185433-A1 | STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND | KCNQ2, RCC1, SFPQ | METTL3 133/4885PLA2G4A 4321/4885MAPT 626/4885 |
| US-11166957-B2 | Antiviral prodrugs and nanoformulations thereof | TYMP, PNP, SLC29A1 | METTL3 466/4885PLA2G4A 1301/4885MAPT 2826/4885 |
| US-20220211716-A1 | ANTIVIRAL PRODRUGS AND NANOFORMULATIONS THEREOF | TYMP, PNP, SLC29A1 | METTL3 466/4885PLA2G4A 1301/4885MAPT 2826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.